MARKSANS · Healthcare · Drug Manufacturers - General
Composite scorecard: 43/100 — Quality 65 · Valuation 10 · Momentum 44
| Share price | ₹266.95 |
| Market cap | ₹12,344 Cr |
| P/E ratio | 29.6 |
| P/B ratio | 4.1 |
| ROCE | 17.5% |
| Dividend yield | 0.32% |
| Book value | ₹66.74 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,951 Cr | ₹420 Cr | 20.0% |
| 2025 | ₹2,623 Cr | ₹383 Cr | 20.0% |
| 2024 | ₹2,177 Cr | ₹315 Cr | 21.0% |
| 2023 | ₹1,852 Cr | ₹265 Cr | 18.0% |
| 2022 | ₹1,491 Cr | ₹187 Cr | 17.0% |
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeuti